Autopsy report · NCT00675441

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

“Terminated due to slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 4 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 2 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Graft-versus-Host Disease

Interventions

Lenalidomide

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
  “Terminated due to low accrual.” (92% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (88% match in meaning)
• Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
  “Terminated due to poor accrual” (85% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (83% match in meaning)
• Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
  “terminated due to administrative reasons.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.